Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nystatin LF (Aronex/Abbott).

S Arikan1, J H Rex

  • 1Hacettepe University Medical School, Department of Microbiology and Clinical Microbiology, Ankara, Turkey. sarikan@metu.edu.tr

Current Opinion in Investigational Drugs (London, England : 2000)
|September 22, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing the dual-use of antifungals and fungal antimicrobial resistance (fAMR) through a One Health approach.

npj antimicrobials and resistance·2026
Same author

<i>In Vivo</i> Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis.

Antimicrobial agents and chemotherapy·2021
Same author

The role of miRNAs targeting K-ras and APC genes in colorectal cancer.

Bratislavske lekarske listy·2020
Same author

Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.

Antimicrobial agents and chemotherapy·2019
Same author

Efficacy of Olorofim (F901318) against <i>Aspergillus fumigatus</i>, <i>A. nidulans</i>, and <i>A. tanneri</i> in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease.

Antimicrobial agents and chemotherapy·2019
Same author

Genetic origin of Behçet's disease population in Denizli, Turkey; population genetics data analysis; historical demography and geographical perspectives based on β-globin gene cluster haplotype variation.

Genes and immunity·2016
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Liposomal nystatin (Nyotran) shows broad in vitro antifungal activity, including against resistant strains. Further trials are underway to evaluate its efficacy for systemic fungal infections and cryptococcal meningitis.

Area of Science:

  • Pharmacology and Mycology
  • Drug Development

Background:

  • Nystatin LF (Nyotran) is an investigational liposomal, intravenous formulation of nystatin.
  • Nystatin is a polyene antifungal agent that targets ergosterol in fungal cell membranes.
  • Traditional nystatin is limited to topical use due to oral ineffectiveness and severe intravenous toxicity.

Purpose of the Study:

  • To develop a systemic antifungal agent effective against a broad spectrum of fungal pathogens.
  • To evaluate the efficacy of liposomal nystatin against clinically relevant filamentous fungi, including those resistant to other antifungals.
  • To assess the efficacy of nystatin LF in treating cryptococcal meningitis through a Phase III clinical trial.

Main Methods:

  • In vitro studies demonstrating antifungal activity against various fungal strains, including resistant ones.

Related Experiment Videos

  • Phase III clinical trial to evaluate the efficacy of nystatin LF against cryptococcal meningitis.
  • Regulatory filings for approval in Spain and planned filings in the US and Europe.

    • Main Results:

    • Demonstrated broad in vitro antifungal activity against clinically relevant filamentous fungi.
    • Showed efficacy against fungal strains resistant to fluconazole and amphotericin B.
    • Phase III trial data collection for cryptococcal meningitis was ongoing, with initial filings based on interim data.

    Conclusions:

    • Liposomal formulation of nystatin (Nyotran) exhibits promising broad-spectrum in vitro antifungal activity.
    • The intravenous formulation targets systemic fungal infections, including those caused by resistant organisms.
    • Further clinical evaluation is necessary to confirm efficacy and safety for systemic use, particularly in cryptococcal meningitis.